|1.||Becker, Richard C: 1 article (12/2009)|
|2.||Chan, Mark Y: 1 article (12/2009)|
12/01/2009 - "REG-1, under development by Regado Biosciences Inc, is an intravenously administered anticoagulant system comprising the Factor IXa-inhibiting aptamer RB-006 and its complementary active control oligonucleotide, RB-007, for the potential treatment of arterial thrombosis. "
12/01/2009 - "REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis."
|2.||Coronary Artery Disease (Coronary Atherosclerosis)
|1.||Factor IXa (Coagulation Factor IXa)